Any feedback?
Literature summary for 3.1.4.53 extracted from
- Phosphodiesterase type 5 inhibitors: unmet needs (2009), Curr. Pharm. Des., 15, 3476-3485.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | PDE5 inhibition is a efficacious oral therapy for erectile dysfunction | Homo sapiens |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| 3-(1-methyl-7-oxo-3-propyl-4,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide | - |
Homo sapiens |  |
| avanafil | - |
Homo sapiens | |
| lodenafil | - |
Homo sapiens | |
| mirodenafil | - |
Homo sapiens | |
| sildenafil | - |
Homo sapiens | |
| tadalafil | - |
Homo sapiens | |
| vardenafil | - |
Homo sapiens | |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| PDE5 | - |
Homo sapiens |
| phosphodiesterase type 5 | - |
Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
